This is a non-randomized, single arm, open-label, single institution, phase I study to
determine the maximum tolerated dose (MTD) of ET190L1 ARTEMIS™ T cells in patients ≥ 18 years
of age with relapsed or refractory CD19+ Non-Hodgkin's lymphoma.
The trial will follow a traditional dose-escalation model to establish the MTD and
recommended phase 2 dose (RP2D) of infused ET190L1 ARTEMIS™ T cells following
lympho-depleting chemotherapy. Two sequential cohorts of patients will be recruited to
fulfill this study, those in the dose escalation cohort (for determination of MTD and RP2D)
and those in the expansion cohort (treated on the RP2D). The study will have concurrent
phases of screening, pre-treatment, treatment, primary follow-up, safety, and survival
follow-up. The total duration of the study involvement for the patient is 15 years. Efficacy
will be assessed until progression and safety will be assessed throughout the full duration
of the study. Twelve to 24 patients will be treated to determine the MTD. Following
determination of the MTD, an expansion cohort consisting of 6 patients per disease subtype
(n= 30) will be recruited.
- Patients with relapsed/refractory CD19+ Non-Hodgkin's lymphoma of the following
- Diffuse large B-cell lymphoma (DLBCL)
- Mantle cell lymphoma (MCL)
- Follicular lymphoma (FL)
- Chronic lymphocytic leukemia and Small lymphocytic lymphoma (CLL/SLL)
- Burkitt's Lymphoma
- Ability to provide written informed consent for the protocol.
- Willingness and ability to comply with scheduled visit, treatment plans, laboratory
tests, and other procedures.
- Age ≥ 18 years old.
- Eastern Cooperative Oncology Group performance status of ≤ 2.
- Evidence of at least one measurable lesion (nodes/nodal masses > 1.5 cm, extranodal
masses >1.0 cm or PET avid lesions consistent with lymphoma) on imaging with the
1. Patients treated with interim chemotherapy for disease control between enrollment
and ET190L1 ARTEMIS™ T cell infusion who do not have measurable disease at
re-screening are still eligible.
2. CLL/SLL with documented B-cell absolute lymphocytosis > 5 x 109 cells/L
peripheral blood or infiltration of lymph nodes and/or bone marrow infiltration
by CLL phenotype cells defined as: clonal B cells with majority population
co-expressing CD5 and CD19, with surface immunoglobulin (sIg, kappa or lambda but
not both) and CD20 (dim), CD23+ (if CD20 or sIg are bright or if CD23 is dim or
negative [atypical CLL phenotype] then FISH for 11:14 translocation must be
performed to differentiate from mantle cell lymphoma).
3. Lesions previously irradiated will be considered measurable only if progression
has been documented following completion of radiation therapy.
- Must have biopsy-proven primary refractory disease or relapsed disease after
front-line chemo-immunotherapy (with anti-CD20 mAb in combination with
anthracycline-based chemotherapy) or at least one of the following:
- For subjects with DLBCL: relapsed or refractory disease after ≥ 2 prior line(s)
of therapy. For both de novo and transformed disease, patients must have received
at least 1 prior regimen with anti-CD20 mAb and anthracycline.
- For subjects with FL or SLL: relapsed or refractory disease after ≥ 2 prior
line(s) of therapy.
- For subjects with CLL: must be relapsed or refractory disease and:
1. with no unfavorable cytogenetics and have failed ≥ 3 prior line(s) of
2. with unfavorable cytogenetics including del17p/mutated p53 or unmutated
immunoglobulin heavy chain variable region relapsed or refractory disease
after ≥ 2 prior line(s) of therapy which must have included ibrutinib.
- For subjects with MCL: relapsed or refractory disease after at least 1 prior
regimen with chemoimmunotherapy.
- For subjects with Burkitt's: relapsed or refractory disease after at least 1
prior line of therapy.
- Any patient, with subtypes listed above, having either failed autologous HSCT
after at least 1 prior regimen, or those patients ineligible for, but not an
appropriate candidate, or not consenting to autologous HSCT.
- Adequate organ function parameters are set according to what the treating physician
defines as adequate organ function and are acceptable for participation in this trial.
These criteria are defined as:
1. Renal function:
1. Creatinine clearance ≥45ml/min
2. Liver function:
1. AST/ALT ≤ 3x the institutional ULN, except for people with liver involvement
by their lymphoma, who may be included if AST/ALT ≤ 5x the institutional
2. Total bilirubin ≤ 2x the institutional ULN with the exception of patients
with Gilbert syndrome; patients with Gilbert syndrome may be included if
their total bilirubin is ≤ 3.0x ULN and direct bilirubin is ≤ 2x ULN
3. Pulmonary function:
1. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea
and pulse oximetry of ≥ 88% on room air.
4. Cardiac function:
1. Must be hemodynamically stable at the time of ET190L1 ARTEMIS™ T cell
administration and have LVEF ≥ 45% confirmed by echocardiogram or MUGA scan
5. Bone marrow reserve without transfusion defined as:
1. Absolute neutrophil count (ANC) ≥ 1,000/mm3
2. Absolute lymphocyte count (ALC) ≥ 300/mm3, and absolute number of CD3+ T
cells > 150/mm3
3. Platelets ≥ 50,000/mm3
4. Hemoglobin ≥ 8 g/dL
- Women who are pregnant will be excluded from the study. A woman of child-bearing
potential, defined as all women physiologically capable of becoming pregnant, will
have a blood pregnancy test and the test must be negative to participate in this
study. Women of child-bearing potential and all male participants must use effective
methods of contraception for at least 12 months following infusion of ET190L1 ARTEMIS™
T cells and until ET190L1 ARTEMIS™ T cells are no longer present by PCR (with
surveillance to cease at 5 years).
1. Medically acceptable contraceptives for females include:
1. Surgical sterilization (such as a tubal ligation or hysterectomy).
2. Approved hormonal contraceptives (such as birth control pills, patches,
implants, or injections).
3. Barrier methods (such as condoms or diaphragms) used with a spermicide.
4. An intrauterine device (IUD).
2. Contraceptive measures such as Plan B, sold for emergency use after unprotected
sex, are not acceptable methods for routine use. If the woman does become
pregnant during this study or if the woman has unprotected sex, she must inform
the study physician immediately.
3. Medically acceptable contraceptives for males include:
1. Surgical sterilization (such as a vasectomy)
2. A condom used with a spermicide
4. Contraceptive measures such as Plan B, sold for emergency use after unprotected
sex, are not acceptable methods for routine use. The man should inform his
partner of the potential for harm to an unborn child. She should know that if
pregnancy occurs, he will need to report it to the study doctor, and she should
promptly notify her doctor.
- Prior Treatment:
1. With any prior anti-CD19/anti-CD19 CAR-T or cellular therapy (prior Blinotumomab
therapy is allowed)
2. Treatment with any prior gene therapy
3. Prior allogeneic hematopoietic stem cell transplant
4. Received chemotherapy, radiation or surgical resection of malignancy within 2
weeks prior to the start of conditioning chemotherapy (day -10 to -5).
- Active, uncontrolled serious infection or medical or psychiatric illness, that in the
investigator's opinion is likely to interfere with participation in this clinical
- Active CNS involvement by malignancy.
- History of seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar
disease, or any autoimmune disease with CNS involvement.
- Active replication of hepatitis B or active hepatitis C (HCV RNA positive). Those with
prior disease who are PCR negative at enrollment and meet liver function eligibility
criterion are eligible.
- Known HIV positive patients
- Patients with unstable angina and/or myocardial infarction within 6 months prior to
- Cardiac arrhythmia not controlled with medical management, evidence of pericardial
effusion on imaging that is compromising function.
- Previous or concurrent malignancy with exception of adequately treated basal cell or
squamous cell carcinoma, in-situ carcinoma of the cervix or breast, treated curatively
and without evidence of recurrence for at least 3 years prior to study drug infusion,
or prostate cancer that was treated with prostatectomy or radiotherapy over 2 years
before day 1 of protocol therapy and patients whose PSA is undetectable at study
- Autoimmune disease or history of primary immunodeficiency (excluding Hashimoto's
thyroiditis, vitiligo, or DM type I)
- Women who are pregnant or breast feeding.